Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients

Joseph Dichiara, Kevin P. Bliden, Udaya S. Tantry, Srivasavi K. Chaganti, Rolf Kreutz, Tania B. Gesheff, Tania A. Geshefe, Yvonne Kreutz, Paul A. Gurbel

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Selected aspirin treated patients may exhibit high platelet reactivity to agonists other than arachidonic acid. This study aimed to determine whether the VerifyNow™ identifies generalized high platelet reactivity supported by correlations with other established methods that stimulate platelets with various agonists. Stable outpatients with coronary artery disease (n = 110) were treated with aspirin in a two 3 x 3 Latin square design (81, 162 and 325 mg/day for 4 weeks each). VerifyNow™ (arachidonic acid (AA) cartridge); light transmittance aggregometry; thrombelastography; PFA-100®; flow cytometry; PlateletWorks®; and urinary 11- dehydro thromboxane levels were measured. Multianalyte profiling measured fibrinogen and von Willebrand factor (vWF). Patients with ≥550 ARU by VerifyNow™ had increased 5 mM AA-, 5 μM ADP-, and 2 μg/mL collagen-induced platelet aggregation compared to patients with

Original languageEnglish (US)
Pages (from-to)414-423
Number of pages10
JournalPlatelets
Volume18
Issue number6
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Arachidonic Acid
Aspirin
Blood Platelets
Thrombelastography
Thromboxanes
von Willebrand Factor
Platelet Aggregation
Adenosine Diphosphate
Fibrinogen
Coronary Artery Disease
Flow Cytometry
Outpatients
Collagen
Light

Keywords

  • Aspirin
  • Platelet reactivity
  • VerifyNow

ASJC Scopus subject areas

  • Hematology
  • Cell Biology

Cite this

Dichiara, J., Bliden, K. P., Tantry, U. S., Chaganti, S. K., Kreutz, R., Gesheff, T. B., ... Gurbel, P. A. (2007). Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients. Platelets, 18(6), 414-423. https://doi.org/10.1080/09537100701206824

Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients. / Dichiara, Joseph; Bliden, Kevin P.; Tantry, Udaya S.; Chaganti, Srivasavi K.; Kreutz, Rolf; Gesheff, Tania B.; Geshefe, Tania A.; Kreutz, Yvonne; Gurbel, Paul A.

In: Platelets, Vol. 18, No. 6, 09.2007, p. 414-423.

Research output: Contribution to journalArticle

Dichiara, J, Bliden, KP, Tantry, US, Chaganti, SK, Kreutz, R, Gesheff, TB, Geshefe, TA, Kreutz, Y & Gurbel, PA 2007, 'Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients', Platelets, vol. 18, no. 6, pp. 414-423. https://doi.org/10.1080/09537100701206824
Dichiara, Joseph ; Bliden, Kevin P. ; Tantry, Udaya S. ; Chaganti, Srivasavi K. ; Kreutz, Rolf ; Gesheff, Tania B. ; Geshefe, Tania A. ; Kreutz, Yvonne ; Gurbel, Paul A. / Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients. In: Platelets. 2007 ; Vol. 18, No. 6. pp. 414-423.
@article{18b87c1932ec405982d1cde54986ce86,
title = "Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients",
abstract = "Selected aspirin treated patients may exhibit high platelet reactivity to agonists other than arachidonic acid. This study aimed to determine whether the VerifyNow™ identifies generalized high platelet reactivity supported by correlations with other established methods that stimulate platelets with various agonists. Stable outpatients with coronary artery disease (n = 110) were treated with aspirin in a two 3 x 3 Latin square design (81, 162 and 325 mg/day for 4 weeks each). VerifyNow™ (arachidonic acid (AA) cartridge); light transmittance aggregometry; thrombelastography; PFA-100{\circledR}; flow cytometry; PlateletWorks{\circledR}; and urinary 11- dehydro thromboxane levels were measured. Multianalyte profiling measured fibrinogen and von Willebrand factor (vWF). Patients with ≥550 ARU by VerifyNow™ had increased 5 mM AA-, 5 μM ADP-, and 2 μg/mL collagen-induced platelet aggregation compared to patients with",
keywords = "Aspirin, Platelet reactivity, VerifyNow",
author = "Joseph Dichiara and Bliden, {Kevin P.} and Tantry, {Udaya S.} and Chaganti, {Srivasavi K.} and Rolf Kreutz and Gesheff, {Tania B.} and Geshefe, {Tania A.} and Yvonne Kreutz and Gurbel, {Paul A.}",
year = "2007",
month = "9",
doi = "10.1080/09537100701206824",
language = "English (US)",
volume = "18",
pages = "414--423",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients

AU - Dichiara, Joseph

AU - Bliden, Kevin P.

AU - Tantry, Udaya S.

AU - Chaganti, Srivasavi K.

AU - Kreutz, Rolf

AU - Gesheff, Tania B.

AU - Geshefe, Tania A.

AU - Kreutz, Yvonne

AU - Gurbel, Paul A.

PY - 2007/9

Y1 - 2007/9

N2 - Selected aspirin treated patients may exhibit high platelet reactivity to agonists other than arachidonic acid. This study aimed to determine whether the VerifyNow™ identifies generalized high platelet reactivity supported by correlations with other established methods that stimulate platelets with various agonists. Stable outpatients with coronary artery disease (n = 110) were treated with aspirin in a two 3 x 3 Latin square design (81, 162 and 325 mg/day for 4 weeks each). VerifyNow™ (arachidonic acid (AA) cartridge); light transmittance aggregometry; thrombelastography; PFA-100®; flow cytometry; PlateletWorks®; and urinary 11- dehydro thromboxane levels were measured. Multianalyte profiling measured fibrinogen and von Willebrand factor (vWF). Patients with ≥550 ARU by VerifyNow™ had increased 5 mM AA-, 5 μM ADP-, and 2 μg/mL collagen-induced platelet aggregation compared to patients with

AB - Selected aspirin treated patients may exhibit high platelet reactivity to agonists other than arachidonic acid. This study aimed to determine whether the VerifyNow™ identifies generalized high platelet reactivity supported by correlations with other established methods that stimulate platelets with various agonists. Stable outpatients with coronary artery disease (n = 110) were treated with aspirin in a two 3 x 3 Latin square design (81, 162 and 325 mg/day for 4 weeks each). VerifyNow™ (arachidonic acid (AA) cartridge); light transmittance aggregometry; thrombelastography; PFA-100®; flow cytometry; PlateletWorks®; and urinary 11- dehydro thromboxane levels were measured. Multianalyte profiling measured fibrinogen and von Willebrand factor (vWF). Patients with ≥550 ARU by VerifyNow™ had increased 5 mM AA-, 5 μM ADP-, and 2 μg/mL collagen-induced platelet aggregation compared to patients with

KW - Aspirin

KW - Platelet reactivity

KW - VerifyNow

UR - http://www.scopus.com/inward/record.url?scp=34548331542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548331542&partnerID=8YFLogxK

U2 - 10.1080/09537100701206824

DO - 10.1080/09537100701206824

M3 - Article

C2 - 17763150

AN - SCOPUS:34548331542

VL - 18

SP - 414

EP - 423

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 6

ER -